Department


Pharmacy Practice

Assistant Professor
Focus: Ambulatory Care/Endocrinology

Contact Information
(518) 694-7415
Matthew.Stryker@acphs.edu


Speaker Request
Matthew D. Stryker, PHARM.D., BCACP, CLS

EDUCATION 

  • PGY1 Pharmacy Residency, Ambulatory Care Focus, Albany College of Pharmacy and Health Sciences, Albany, New York
  • Pharm.D., Wegmans School of Pharmacy at St. John Fisher College, Rochester, New York
  • Bachelor of Science in Biology, State University of New York at Geneseo, Geneseo, New York

COURSES TAUGHT AT ACPHS 

  • Pathophysiology, Therapeutics, Pharmacology and Medicinal Chemistry Endocrine (PTP 425)
  • Facilitator, Integrated Problem Solving Workshop IV (IPS 502)
  • Facilitator, Integrated Problem Solving Workshop III (IPS 401)

PRACTICE SITE AND CLINICAL PHARMACY SERVICES

  • Albany Medical Center – Division of Community Endocrinology
    • 1365 Washington Avenue, Suite 300, Albany, New York 12206
  • Smoking, Lipids, Obesity – Cardiovascular Risk Reduction (SLO-CVD) Service
    • Value-added pharmacotherapy services include: advanced lipid management, weight-loss and smoking cessation

ACADEMIC/RESEARCH INTERESTS 

  • Clinical trial design and implementation
  • Dyslipidemias and antilipemic pharmacotherapy
  • Emergency preparedness
  • Endocrine-based disorders
  • Interprofessional education 

SELECTED PUBLICATIONS 

  • Stryker MD, Schulman-Marcus J, Sidhu MS. The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA1c(v)-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al. Cardiovasc Drugs Ther. 32. United States2018. p. 1-3.
  • Stryker MD, Kane MP, Busch RS. A Real-World, Observational Study of Weekly Exenatide Added to Basal Insulin in Patients With Type 2 Diabetes Mellitus (NCT02895672). Endocrinol Diab Metab. 2017;00:e4. http://doi.org/10.1002/edm2.4
  • Stryker M, Bizier J, Kane M. Follow-Up Real-World Data in a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Cohort: Results from a Pharmacist-Run Clinic. J Clin Lipidol. 2017;11(3):835-36.
  • Bizier J, Stryker M, Kane M. Extended-Use, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (PCSK9i) Data in Patients With Diabetes Mellitus: A Pharmacist-Led Initiative. J Clin Lipidol. 2017;11(3):778.
  • Stryker M, Kane M, Busch R. Lack of Cross-Reactivity Following a Switch from Alirocumab to Evolocumab. Excerpts in Pharmacy Research Journal. Forthcoming 2016.
  • Stryker M, Kane M, Busch R. A Pharmacist-Run Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Clinic: Short-Term Results and Practical Strategies. Pharmacotherapy 2016;36(7)e83-e138.
  • Stryker M, Kane M, Busch R. An Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Patients with Diabetes Mellitus. J Clin Lipidol 2016; 10:720.

SELECTED PRESENTATIONS

  • Stryker M, Kane M, Busch R. A Real-World, Observational Study of Weekly Exenatide Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus (NCT02895672). Abstract Identification: 200. 2018 American Association of Clinical Endocrinologists Annual Meeting.
  • Diabetes Mellitus Related Updates for the Ambulatory Care Pharmacist. 2017 Updates Plus in Ambulatory Care Pharmacy Webinar. American College of Clinical Pharmacy.
  • Stryker M, Bizier J, Kane M. Follow-Up Real-World Data in a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Cohort: Results From A Pharmacist-Run Clinic. Abstract Identification: 201. 2017 National Lipid Association’s Scientific Sessions.
  • Bizier J, Stryker M, Kane M. Extended-Use, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Data in Patients with Diabetes Mellitus: A Pharmacist-Led Initiative. Abstract Identification: 111. 2017 National Lipid Association’s Scientific Sessions.
  • Stryker M, Kane M, Busch R, Hamilton R. An Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Patients with Diabetes Mellitus. Abstract Identification: 187. 2016 National Lipid Association’s Scientific Sessions.
  • Stryker M, Kane M, Busch R, Hamilton R. A Pharmacist-Run Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Clinic: Short-Term Results and Practical Strategies. Poster Number: 97. American College of Clinical Pharmacy’s 2016 Virtual Poster Symposium.
  • Stryker M, Kane M, Busch R, Hamilton R. Evaluating the Off-Label Use of Once-Weekly Exenatide in Combination with Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus. Submission Number: 388695. 2015 American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition.
  • Sodium-Glucose Cotransporter-2 Inhibitor Therapy and Euglycemic Diabetic Ketoacidosis: Fact or Fiction. 2015 American College of Clinical Pharmacy – New York State Chapter Annual Meeting. 

HONORS AND ACHIEVEMENTS

  • Recipient, Scholarship of Discovery Intramural Research Grant Program, May 2018
  • Clinical Lipid Specialist, Accreditation Council for Clinical Lipidology, May 2018
  • Board Certified Ambulatory Care Pharmacist, Board of Pharmacy Specialties, November 2017
  • Teaching and Learning Program – Albany College of Pharmacy and Health Sciences

PROFESSIONAL ORGANIZATION MEMBERSHIPS

  • Associate Member, National Lipid Association (NLA)
  • American College of Clinical Pharmacy (ACCP) 
    • Endocrine and Metabolism Practice Research Network
  • Rho Chi Honor Society - Delta Zeta Chapter

CONFERENCES AND PRESENTATIONS

Farina K, Stryker M. Altered thyroid function tests (TFTs) and unnecessary thioamide therapy following treatment with high-dose biotin (300mg). ASHP Midyear Clinical Meeting, Anaheim CA, December 2-6, 2018.